Target intelligence / Profile preview

Mesothelin (Mus musculus) (Msln)

Target
Msln
Molecular classification
GPI-anchored protein, Cell surface glycoprotein, Tumor-associated antigen
01

Overview

Mesothelin is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein that is normally expressed at low levels on mesothelial cells lining the pleura, peritoneum, and pericardium (UniProt Q61468). In Mus musculus, the protein is encoded by the Msln gene and is processed from a 71 kDa precursor into a 31 kDa secreted fragment known as megakaryocyte-potentiating factor (MPF) and a 40 kDa membrane-bound mature mesothelin (NCBI Gene: 56047). While its exact physiological function remains elusive, it is hypothesized to play a role in cell adhesion and signaling, particularly through its interaction with MUC16 (CA125) (PubMed: 15310686). Mesothelin is highly overexpressed in several human malignancies, including mesothelioma, pancreatic, and ovarian cancers, making it a prominent target for immunotherapy (PubMed: 17005656). In preclinical research, mouse mesothelin is frequently studied to evaluate the efficacy and safety of mesothelin-targeted therapies, such as CAR T-cells and antibody-drug conjugates, using syngeneic mouse models (PubMed: 28235901). These therapeutic strategies aim to exploit the high tumor-to-normal tissue expression ratio to achieve selective anti-tumor activity while monitoring for potential on-target off-tumor toxicities in serosal tissues.

Other names
Pre-pro-megakaryocyte-potentiating factorMPFCAK1 antigen
02

Mechanism of action

Binding to cell-surface mesothelin to facilitate immune-mediated lysis (via CAR-T or ADCC) or to deliver cytotoxic payloads (via ADCs), thereby inducing apoptosis in overexpressing tumor cells.

03

Biological functions

Cell adhesionCell signaling
04

Disease associations

MesotheliomaPancreatic adenocarcinomaOvarian cancerLung adenocarcinoma
05

Safety considerations

On-target off-tumor toxicity to normal mesothelial cellsPotential for pleuritis, peritonitis, or pericarditisDose-limiting toxicities in clinical trials such as ocular toxicity for certain ADCs
06

Interacting drugs

Amatuximab

4 more in the full profile.

07

Biomarkers

Soluble mesothelin-related peptide (SMRP)

Beyond the preview

Go deeper on Mesothelin (Mus musculus) (Msln).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mesothelin (Mus musculus) (Msln).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call